An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

MIAMI - Drugs like Ozempic, Wegovy and Mounjaro have transformed the weight loss industry, becoming household names seemingly overnight. Touted as game-changers, these medications not only help ...

Hannah's doctor prescribed Saxenda - part of a group of drugs known as GLP-1 receptor agonists - and she began the daily injections. Drugs like Ozempic, Mounjaro and Saxenda have swept the globe ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications ... the same active ingredient found in Mounjaro. While Zepbound is FDA-approved ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications ... 12.8% to 14.7% of their body weight. In comparison, placebo groups saw weight ...

The names at the forefront of weight loss drugs are Eli Lilly, the U.S. manufacturer of Mounjaro and Zepbound; and Novo Nordisk, the Danish maker of Ozempic, Saxenda, and Wegovy. However ...